Omadacycline
| Clinical data | |
|---|---|
| Pronunciation | oh mad" a sye' kleen |
| Trade names | Nuzyra |
| Other names | PTK-0796, BAY 73-6944 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618066 |
| License data |
|
| Routes of administration | By mouth, intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C29H40N4O7 |
| Molar mass | 556.660 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Omadacycline, sold under the brand name Nuzyra, is a broad spectrum antibiotic medication belonging to the aminomethylcycline subclass of tetracycline antibiotics. In the United States, it was approved in October 2018, for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections.